Navigation Links
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Date:3/16/2012

d group to help make NUEDEXTA available to patients and physicians worldwide," said Rohan Palekar, senior vice president and chief commercial officer of Avanir. "The growth opportunity that lies ahead for Avanir is incredible and I look forward to the chance to positively affect the lives of patients suffering from pseudobulbar affect and other CNS disorders."

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

©2012 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, th
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Avanir Pharmaceuticals to Participate in Two Conferences in March
2. Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System
3. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
4. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
5. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
6. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
7. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
8. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
9. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
10. Avanir Pharmaceuticals to Participate in Two Investor Conferences
11. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Calif. , Aug. 3, 2015  Depomed, Inc. ... commented on Horizon Pharma plc,s (NASDAQ: HZNP ) ... Board of Directors ("Depomed Board") set a record date ... meeting. The Depomed Board will review ... request is received today and contains the information required ...
(Date:8/3/2015)... , Aug. 3, 2015  Dr. ... Orthopaedic & Spine Center today, providing ... manage their chronic pain through psychological counseling and ... is a Fellowship-trained, certified medical psychologist with an ... His vast experience ranges from assessment and treatment ...
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
Breaking Medicine Technology:Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Orthopaedic & Spine Center Introduces New Pain Psychologist 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay $56.9 million to ... a claimant alleged to have suffered an arterial blood clot including stroke and heart ... Yasmin and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany ... 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in ... whose mission is to develop technology for the sake of humanity – continues ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive and ... from healthcare organizations with access to the tactics, techniques and practices required to ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number of ... to market research compiled for the National Association of Dental Laboratories ( NADL ... Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists will ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... the most recent,edition of the local AT&T phone book ... entirely different kind of service -- an adult,entertainment hotline. ... found they could get anything they wanted for "$3.99 ... Both an advertisement and a phone number listing ...
... and surgery is not possible, transplanting stem cells from the patient,s ... this chronic disease. , The procedure has been ... the disease has been shown in 80% of cases, and considerable ... Since August 2008, Hospital Clnic has used this therapy in a ...
... Pa., Feb. 19 /PRNewswire-USNewswire/ -- Pennsylvania,s ... CHIP -- has launched a new Spanish-language Web ... who are the state,s fastest growing ethnic group. ... uninsured, there are more than 85,000 uninsured Latinos ...
... Stop this EpidemicAetna, Blue Cross and Blue Shield of ... and WellPoint along with American Academy of Pediatrics and ... epidemicNEW YORK, Feb. 19 Today, The Alliance ... the American Heart Association and the William J. Clinton ...
... PITTSBURGH, Feb. 19 Mylan Inc. (Nasdaq: MYL ... J. Coury will preside over the NASDAQ Stock Market opening ... Coury will ring the opening bell to celebrate the company,s ... common stock began trading on NASDAQ Dec. 29, 2008. The ...
... causes alteration in several cellular mechanisms, and leads ... phenomena are associated to significant changes in the ... memory. Although inhibition of proteasome function has been ... (ALD), why proteasome dysfunction may enhance hepatotoxicity is ...
Cached Medicine News:Health News:Monroe Hospital: Laughter is Best Medicine for Unwelcome Publicity 2Health News:New therapy with stem cells to treat Crohn's disease 2Health News:New therapy with stem cells to treat Crohn's disease 3Health News:New therapy with stem cells to treat Crohn's disease 4Health News:New therapy with stem cells to treat Crohn's disease 5Health News:CHIP Launches New Web Site Serving Pennsylvania's Fast-Growing Latino Population 2Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 2Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 3Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 4Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 5Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 6Health News:Alliance for a Healthier Generation Expands Efforts to Combat Childhood Obesity with Launch of Landmark Healthcare Initiative 7Health News:Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell 2Health News:Proteasome inhibition affects epigenetic mechanisms 2